MedTrace Logo

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-06-19

No results posted yet for this study

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

BIOLOGICAL

OVA BiP peptide

BIOLOGICAL

gp209-2M antigen

BIOLOGICAL

recombinant 70-kD heat-shock protein

BIOLOGICAL

tyrosinase peptide

Sponsors & Collaborators

Principal Investigators

  • Philip O. Livingston, MD · Memorial Sloan Kettering Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-06-30
Primary Completion
2002-06-30
Completion
2002-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005633 on ClinicalTrials.gov